There were 689 press releases posted in the last 24 hours and 166,996 in the last 365 days.

I-Mab Announces Upcoming Participation at March Conferences

/EIN News/ -- SHANGHAI, China and ROCKVILLE, MD., Feb. 25, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in March. Management presentation details are as follows:

CD47|SIRPα Summit
Presentation: Wednesday, March 18, 2020 at 4:25 p.m. ET
Presenter: Dr. Claire Xu, MD, U.S. Site Head
Location: Boston University’s Metcalf Trustee Center, Boston, MA

Panel Discussion: Wednesday, March 18, 2020 at 4:50 p.m. ET
Panelist: Dr. Claire Xu, MD, U.S. Site Head
Location: Boston University’s Metcalf Trustee Center, Boston, MA

For more information, please visit https://www.cd47sirpa.com.

Morgan Stanley 10th Annual Hong Kong Investor Summit (Virtual)
Open Session: Monday, March 23, 2020 at 9:30 a.m. Hong Kong Time
Presenter: Dr. Jingwu Zang, Founder & Honorary Chairman, Dr. Joan Huaqiong Shen, Director & Chief Executive Officer, and Mr. Jielun Zhu, Director & Chief Financial Officer
One on one meeting: March 23 – 24, 2020

For more information, please contact virtualsummit@morganstanley.com
or contact your Morgan Stanley representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. Company’s mission is to bring transformational medicines to patients through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. I-Mab has offices in China and the United States. For more information, please visit http://ir.i-mabbiopharma.com/.

For more information, please contact:

I-Mab
Jielun Zhu, CFO
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Investor and Media Inquiries:
Americas and Europe
Steve Klass
Burns McClellan
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006

Asia
Emilie Wu
The Piacente Group, Inc.
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

Distribution channels: Culture, Society & Lifestyle, Technology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.